The case of radiation pneumonitis reported in this study was attributed to treatment and, as a result, sorafenib was discontinued at 2.5 months post-treatment. The estimated pulmonary radiation exposure was 25 Gy, slightly below the recommended threshold of 30 Gy in order to mitigate the risk of pulmonary tissue damage. The patient had no prior history of chronic obstructive pulmonary disease that would have increased the risk of lung tissue damage. The nature and frequency of serious adverse events observed in the current study are not unexpected for this population of HCC BYL719 patients with advanced disease against a background of cirrhosis, two-thirds of whom presented with macrovascular invasion, extrahepatic disease and/or liver dysfunction. In a European Phase II study including a similar proportion of patients with BCLC stage B and C, Mazzaferro et al. 2013 recently reported a 23% and 36% rate of liver decompensation at 3 and 6 months, respectively after radioembolization. While investigators from Chicago observed that in patients with PVT, 55% of patients decompensated from Child-Pugh A to B by the time of progression at 5.6 months after radioembolization. The one case of possible radiation/drug-induced liver disease who expired approximately 3.5 months after commencing therapy points to the tenuous condition that these patients often present with. The limitations of this study are its small size and single-arm design. There was a significant overlap between the patient population in this study and other published studies with sorafenib in predominantly advanced HCC, thus allowing for meaningful comparisons.Compares favorably with the 2–9% partial response and 35–95% disease control rate of sorafenib alone or in combination with either conventional or drug-eluting TACE. In an era characterised by lack of suitable organs for transplantation, continuous flow left ventricular assist devices bridge patients with end-stage heart failure to transplantation, to further decision, or to recovery, or are implanted as destination therapy. Despite progressive improvements in technologies, intraoperative and perioperative management, favourable outcomes still depend on proper patient selection and strategic timing of implantation. Indications, absolute or relative contraindications are not universally accepted and contrasting data have been published. With worsening of clinical status of ESHF patients, increase the need for a mechanical circulatory support as the perioperative risk, resulting in a greater exertion in managing the timing of implant. Indeed, in many centers, LVAD implantation is anticipated, preferably before that the patient experiences hemodynamic collapse. Adverse outcomes and development of multi-organ failure in LVAD-patients are related to the activation of systemic inflammation, although mechanisms underlying the multi-organ deterioration remain still poorly understood. The levels of interleukin -6 and IL-8, crucial cytokines for the activation of systemic inflammatory pathways, and neopterin.